| HOME >> BIOLOGY >> TECHNOLOGY |
Irregular Heartbeat Is Side Effect of Common Osteoporosis Medications
PHILADELPHIA, Oct. 27 /PRNewswire/ -- People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study. The research, presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that people taking alendronate or zoledronic acid, two common medications to prevent or slow the occurrence of osteoporosis, were significantly more likely to experience serious AF, including hospitalization or death, compared with placebo.
"Atrial fibrillation can be serious if it is persistent or occurs in people with preexisting heart disease or hypertension," said Jennifer Miranda, MD, Jackson Memorial Hospital, Miami, FL. "If left untreated, it can lead to pulmonary edema, congestive heart failure, or the formation of a blood clot that can cause a brain embolism and stroke."
In a metaanalysis, Dr. Miranda and colleagues from the University of Miami evaluated the relationship between the use of bisphosphonates and AF, a condition that can produce a wide range of symptoms, including light-headedness, palpitations, chest pain, and shortness of breath, or no symptoms at all. Three studies met eligibility criteria and included a total of 16,322 patients, of whom 76 to 100 percent were women using bisphosphonates for osteoporosis with a mean age range 69 to 75 years. Patients in the study were taking alendronate or zoledronic acid. The analysis showed that 2.5 to 3 percent of patients taking bisphosphonates experienced atrial fibrillation and 1 to 2 percent experienced serious AF, including hospitalization or death. Patients taking bisphosphonates were more likely to experience AF than patients receiving placebo and up to two times more likely to experience serious AF than patients receiving placebo.
"In patients with increased risk
'/>"/>
| SOURCE American College of Chest Physicians Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
2. Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World
3. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
4. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
7. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
8. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
9. China Nepstar Chain Drugstore to Announce Second Quarter 2008 Financial Results on August 27
10. drugstore.com, inc. to Announce Second Quarter 2008 Results During Conference Call on Monday, July 28, 2008 at 5:00 p.m. ET
11. Teaching old drugs new tricks
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |